TaiMed Biologics Inc.  announced today (14th) that it has officially signed an exclusive sales and marketing agreement with AcedrA for the HIV new drug Trogarzo in the Middle East and North Africa. AcedrA will be responsible for applying for drug certifications in the authorized regions, as well as promoting and commercializing the product. Before obtaining approval from regulatory authorities, AcedrA will supply Trogarzo through a "named patient program" in accordance with local regulations. 

AcedrA Pharmaceutical Company (also known as AcedrA BioPharmaceuticals) is a drug marketing company dedicated to unmet medical and commercial needs in the Middle East and Africa. Headquartered in Riyadh, the capital of Saudi Arabia, it has offices in the United Arab Emirates, Dubai, and Tunisia. The company focuses on marketing drugs in specialized fields such as rare diseases, orphan drugs, hematology, oncology, metabolic diseases, genetic diseases, recombinant technology, neurology, and biosimilars. The agreement grants AcedrA exclusive marketing rights for Trogarzo in the following Middle Eastern and North African countries: Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Bahrain, Oman, Jordan, Egypt, Lebanon, Iraq, Libya, Tunisia, Algeria, Morocco, and Sudan. 

Chairman James Chang stated, "Trogarzo is currently mainly sold in the United States. However, our company has officially signed an exclusive sales and marketing agreement with AcedrA for the HIV new drug Trogarzo in the Middle East and North Africa. This move will help expand the user base of Trogarzo, thereby increasing the company's future revenue and positively and profoundly impacting the overall interests and long-term value of the company."